2014
AT-23A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL
Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Armstrong T, Aldape K. AT-23A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL. Neuro-Oncology 2014, 16: v13-v13. PMCID: PMC4217801, DOI: 10.1093/neuonc/nou237.23.Peer-Reviewed Original ResearchDose-dense temozolomideClinical trialsPredictive markerFirst prospective clinical trialPhase II studyPrimary CNS tumorsProspective clinical trialsPossible predictive markerPotential predictive markerPatient reported outcomesSubsequent clinical trialsMGMT promoter statusMedian KPSMedian progressionPrimary endpointRecurrent diseaseII studyOverall survivalSymptom burdenMedian ageInitial treatmentCNS tumorsExtensive resectionStandard treatmentPRO collection
2007
Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report
Grimm S, Pulido J, Jahnke K, Schiff D, Hall A, Shenkier T, Siegal T, Doolittle N, Batchelor T, Herrlinger U, Neuwelt E, Laperriere N, Chamberlain M, Blay J, Ferreri A, Omuro A, Thiel E, Abrey L. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Annals Of Oncology 2007, 18: 1851-1855. PMID: 17804469, DOI: 10.1093/annonc/mdm340.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCombined Modality TherapyConsensusEye NeoplasmsFemaleHIV SeronegativityHumansLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsPrimary intraocular lymphomaOverall survivalMedian timeFocal therapyPrimary central nervous system lymphomaMedian ECOG performance statusCentral nervous system lymphomaTreatment typeECOG performance statusPositive CSF cytologyNervous system lymphomaBrain relapseMedian PFSMedian progressionPIOL patientsUncommon subsetIntraocular lymphomaPerformance statusRelapse patternsRetinal biopsyTreatment toxicityMedian ageSystem lymphomaInitial treatmentCSF cytology